Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Annals of Oncology

• Publication date

  1996-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.ANNONC.A010717PMID 8905026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic Therapy of Advanced Breast Cancer

  2012cited by this paper
• Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.

  1996cited by this paper
• Cancer statistics, 1996

  1996cited by this paper
• Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

  1995cited by this paper
• Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

  1995influential reference
• The emerging role of paclitaxel in breast cancer therapy.

  1995cited by this paper
• Treatment of metastatic breast cancer with paclitaxel and doxorubicin.

  1995cited by this paper
• Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion.

  1994cited by this paper
• Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.

  1994cited by this paper
• The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

  1993cited by this paper
• Clinical pharmacology of Taxol.

  1993cited by this paper
• Clinical pharmacology of Taxol.

  1993cited by this paper
• Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.

  1993cited by this paper
• Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.

  1993cited by this paper
• Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

  1993cited by this paper
• A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.

  1991cited by this paper
• How to improve cytotoxic therapy in advanced breast cancer.

  1990cited by this paper
• Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

  1990cited by this paper
• The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

  1990cited by this paper
• Right and left ventricular ejection fraction and left ventricular volume changes at rest and during exercise in normal subjects.

  1984cited by this paper
• Cancer of the breast: the past decade (second of two parts).

  1980cited by this paper
• Adriamycin cardiotoxicity: a survey of 1273 patients.

  1979cited by this paper
• Risk factors for doxorubicin-induced congestive heart failure.

  1979cited by this paper
• Pigmentation of the tongue after treatment with adriamycin.

  1976cited by this paper
• Pigmentation of the tongue after treatment with adriamycin.

  1976cited by this paper
• Adriamycin (NSC-123127) toxicity: unusual melanotic reaction.

  1974cited by this paper
• [Cancer of the breast].

  1961cited by this paper
• CANCER OF THE BREAST

  1941cited by this paper

• CD20 targeted nanomedicine for GCB-diffuse large B-cell lymphoma through synergistic effects of apoptosis and ferroptosis

  2025cites this paper
• Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis

  2025cites this paper
• Co-Encapsulation of Doxorubicin HCl and Paclitaxel in Nanovesicles for Enhanced Breast Cancer Therapy

  2025cites this paper
• [18F]-FLT-PET to evaluate how the sequencing of chemotherapies impacts the efficacy of combination treatment in mouse models of triple-negative breast cancer

  2025cites this paper
• Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery

  2025cites this paper
• Multifaced Anticancer Potential of Doxorubicin: Spotlight on Breast Cancer

  2025cites this paper
• PanThera: predictive analysis of higher-order combination therapies using deep neural networks

  2025cites this paper
• Targeted Nanoparticle Delivery of Lapatinib for Cancer Therapy: Progress, Challenges, and Future Directions

  2025cites this paper
• Комбинированная или монохимиотерапия при метастатическом раке молочной железы

  2025cites this paper
• Advances in Microfluidic‐Based Core@Shell Nanoparticles Fabrication for Cancer Applications

  2024cites this paper
• Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

  2024cites this paper
• Palladium catalysed cross coupling reactions on 2,3-isoxazol-17α-ethynyltestosterone, their anti-cancer activity, molecular docking studies and ADMET analysis.

  2024cites this paper
• Microfluidic chip for synergic drugs assay in 3D breast cancer cell

  2024cites this paper
• An integrated approach to understand the regulatory role of miR-27 family in breast cancer metastasis

  2024cites this paper
• Multifactorial drug carrier system bringing both chemical and physical therapeutics to the treatment of tumor heterogeneity.

  2024cites this paper
• Light emitting diode (LED) irradiation of liposomes enhances drug encapsulation and delivery for improved cancer eradication.

  2024cites this paper
• Co-delivery of Doxorubicin and Paclitaxel via Noisome Nanocarriers Attenuates Cancerous Phenotypes in Gastric Cancer Cells.

  2023cites this paper
• MOF-Thermogel Composites for Differentiated and Sustained Dual Drug Delivery.

  2023cites this paper
• Lupeol synergizes with doxorubicin to induce anti-proliferative and apoptotic effects on breast cancer cells

  2022cites this paper
• At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy

  2022cites this paper
• Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience

  2021cites this paper
• Expression and Functional Contribution of Different Organic Cation Transporters to the Cellular Uptake of Doxorubicin into Human Breast Cancer and Cardiac Tissue

  2021cites this paper
• Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease

  2021cites this paper
• Ionic Hydrogel with Stimuli-Responsive, Self-healable and Injectable Characteristics for the Targeted and Sustained Delivery of Doxorubicin in the Treatment of Breast Cancer

  2021cites this paper
• Microtubule Inhibitors and Cardiotoxicity

  2021cites this paper
• Glutathione-sensitive and folate-targeted nanoparticles loaded with paclitaxel to enhance oral squamous cell carcinoma therapy.

  2020cites this paper
• LHRH/TAT dual peptides-conjugated polymeric vesicles for PTT enhanced chemotherapy to overcome hepatocellular carcinoma

  2020cites this paper
• Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium

  2020cites this paper
• Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction

  2019cites this paper
• Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

  2019cites this paper
• Estrogen-dependent disruption of intracellular iron metabolism augments the cytotoxic effects of doxorubicin in select breast and ovarian cancer cells

  2019cites this paper
• 3D printed dual macro-, microscale porous network as a tissue engineering scaffold with drug delivering function

  2019cites this paper
• Cardiac microtubules in health and heart disease

  2019cites this paper
• Multilayer architecture microfluidic network array for combinatorial drug testing on 3D-cultured cells

  2019cites this paper
• Coaxial Electrohydrodynamic Atomization for the Production of Drug-Loaded Micro/Nanoparticles

  2019cites this paper
• Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma

  2019cites this paper
• Synergistic Activation of Doxorubicin against Cancer : A Review

  2018cites this paper
• A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy.

  2018cites this paper
• Cardiovascular sequelae of breast cancer treatments: A review.

  2018cites this paper
• Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods.

  2018cites this paper
• Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.

  2017cites this paper
• Chemotherapy-Associated Arrhythmias

  2017cites this paper
• Molecules, Drugs, and First-Line Therapies: A Guide for the Cardiologist

  2017cites this paper
• Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.

  2017cites this paper
• Biological effects of amphiphilic copolymer nanoparticle-encapsulated multi-target chemotherapeutic drugs on MCF-7 human breast cancer cells

  2017cites this paper
• Precise ratiometric loading of PTX and DOX based on redox-sensitive mixed micelles for cancer therapy.

  2017cites this paper
• Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment

  2017cites this paper
• Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment.

  2016cites this paper
• RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

  2016cites this paper
• Cancer drug related cardiotoxicity during breast cancer treatment

  2016cites this paper
• Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer

  2016cites this paper
• Microbial transformation of danazol with Cunninghamella blakesleeana and anti-cancer activity of danazol and its transformed products.

  2016cites this paper
• [Validation of the Antiproliferative Effects of Euphorbia tirucalli Extracts in Breast Cancer Cell Lines].

  2016cites this paper
• Validation of the antiproliferative effects of Euphorbia tirucalli extracts in breast cancer cell lines

  2016cites this paper
• The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

  2016cites this paper
• Análisis de la efectividad del tratamiento neoadyuvante al añadir docetaxel secuencial a fluorouracilo, epirrubicina y ciclofosfamida en pacientes con cáncer de mama avanzado: resultados preliminares de respuesta tumoral

  2015cites this paper
• Screening of South African medicinal plant Euphorbia tirucalli for anticancer properties

  2015cites this paper
• A Prospective Comparative Study of the Toxicity Profile of 5-Flurouracil, Adriamycin, Cyclophosphamide Regime VS Adriamycin, Paclitaxel Regime in Patients with Locally Advanced Breast Carcinoma.

  2015cites this paper
• Using a peptide segment to covalently conjugate doxorubicin and taxol for the study of drug combination effect

  2015cites this paper
• Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review.

  2015cites this paper
• The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.

  2015cites this paper
• Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast Cancer

  2014cites this paper
• A novel targeting drug carrier to deliver chemical bonded and physical entrapped anti-tumor drugs.

  2014cites this paper
• Three model shapes of Doxorubicin for liposome encapsulation

  2014cites this paper
• Cardiotoxicity of systemic agents used in breast cancer.

  2014cites this paper
• Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity

  2014cites this paper
• Rational design of nanoparticles to improve anticancer drug delivery

  2014cites this paper
• Apoptotic cascade inspired lipid nanovesicles show synergism with encapsulated paclitaxel in chemoresistant colon carcinoma.

  2014cites this paper
• A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.

  2014cites this paper
• A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles.

  2014cites this paper
• pH- and thermosensitive thin lipid layer coated mesoporous magnetic nanoassemblies as a dual drug delivery system towards thermochemotherapy of cancer.

  2014cites this paper
• Cardiovascular Toxicity of Common Chemotherapy Drugs Used to Treat Breast Cancer: An Overview

  2014cites this paper
• WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells.

  2014cites this paper
• Sub-100 nm biodegradable nanoparticles: in vitro release features and toxicity testing in 2D and 3D cell cultures

  2013cites this paper
• Fabrication of core–shell micro/nanoparticles for programmable dual drug release by emulsion electrospraying

  2013cites this paper
• Evaluation of cytotoxicity, biophysics and biomechanics of cells treated with functionalized hybrid nanomaterials

  2013cites this paper
• Weekly paclitaxel--an effective treatment for advanced breast cancer.

  2013cites this paper
• High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells

  2013cites this paper
• Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery

  2012cites this paper
• Lithium attenuates peripheral neuropathy induced by paclitaxel in rats.

  2012cites this paper
• Cancer drugs : highlighting the molecular mechanisms of cardiotoxicity : commentary

  2012cites this paper
• The Taxoids

  2012cites this paper
• Equilibrium radionuclide ventriculography in the assessment of cardiotoxicity of chemotherapy and chemoradiotherapy in patients with breast cancer.

  2012cites this paper
• Co-delivery strategies based on multifunctional nanocarriers for cancer therapy.

  2012cites this paper
• Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer. Single institution experience.

  2012cites this paper
• Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis

  2012cites this paper
• TAC Protocol in Early Breast Cancer Al Amal Hospital Experience

  2011cites this paper
• pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel.

  2011cites this paper
• The microtubule as a breast cancer target

  2011cites this paper
• Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

  2011cites this paper
• Radiotherapy of solitary plasmacytoma

  2011cites this paper
• ErbB signaling in cardiac development and disease.

  2010cites this paper
• Chemotherapy dose-intensification in breast cancer : is more better?

  2010cites this paper
• Altered metabolism of daunorubicin and doxorubicin by genetic variants of human aldo-keto and carbonyl reductases

  2010cites this paper
• Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.

  2009cites this paper
• Adjuvant chemotherapy.

  2009cites this paper
• Population pharmacokinetics of doxorubicin in Indian cancer patients using NONMEM

  2009cites this paper
• Ultrafine PEG-PLA fibers loaded with both paclitaxel and doxorubicin hydrochloride and their in vitro cytotoxicity.

  2009cites this paper
• Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer

  2008cites this paper
• Advanced Breast Cancer: Treatment with Docetaxel/Epirubicin

  2008cites this paper